Seehofer D, Neuhaus P
Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Allgemein-, Visceral- und Transplantationschirurgie, Berlin, Germany.
Zentralbl Chir. 2011 Aug;136(4):343-51. doi: 10.1055/s-0031-1271579. Epub 2011 Aug 23.
Surgical resection is the only chance of cure for patients with colorectal liver metastases und significantly improves patient survival. The percentage of patients who can undergo curative resection as well as the survival after liver resection can be increased by using modern multimodal treatment algorithms. This has been achieved by not only innovations in pre- and postoperative chemotherapy but also by new surgical and interventional techniques and last but not least by individualisation of chemotherapeutic regimens. Due to the high number of new treatment modalities, a generally accepted treatment algorithm cannot be provided so far for all subgroups of the inhomogeneous group of patients with colorectal liver metastases. In the present review the current status of multimodal therapy is outlined and the pending questions mentioned.
手术切除是结直肠癌肝转移患者唯一的治愈机会，能显著提高患者生存率。通过采用现代多模式治疗方案，可增加能够接受根治性切除的患者比例以及肝切除术后的生存率。这不仅通过术前和术后化疗的创新得以实现，还得益于新的手术和介入技术，最后但同样重要的是化疗方案的个体化。由于新治疗模式众多，目前还无法为结直肠癌肝转移这一异质性患者群体的所有亚组提供普遍接受的治疗方案。在本综述中，概述了多模式治疗的现状并提及了悬而未决的问题。
